Clinical trials: Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS
The purpose of this study is to evaluate the safety and efficacy of HLA-haplo matched Allogenic Bone Marrow Derived stem cells("HYNRCS-Allo-ALS-02 inj"), through intrathecal delivery for the repeated treatment after 6 months of…
- Trial name
- NCT03214146
- Testing
- HYNRCS-Allo inj
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Hanyang University Seoul Hospital
Amyotrophic Lateral Sclerosis (ALS)
Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)
Neuroinflammation has recently emerged as a significant contributor to motor neuron damage. ALS tissue is characterized by inflammatory changes that are observed in both sporadic and familial ALS and in the ALS superoxide…
- Trial name
- NCT00231140
- Testing
- Thalidomide (drug)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
ALS
A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)
The causes of ALS are largely unknown. However, mitochondrial dysfunction, resulting in impaired energy production, oxidative stress and apoptosis, may play a key role in ALS progression.
- Trial name
- NCT03506425
- Testing
- Triheptanoin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Richard Bedlack, M.D., Ph.D.
Efficacy and Safety
Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, affects motor neurons, causing progressive muscle atrophy and weakness.
- Trial name
- NCT06351735
- Testing
- Deep cervical lymph node-vein bypass surgery
- Volunteers
- 3 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
ALS (Amyotrophic Lateral Sclerosis)
Characterization of Platelet Molecular Profiles in ALS for the Identification of Specific Diagnostic Biomarkers - A Pilot Study
The search for diagnostic biomarkers that can be used routinely is a major challenge to manage Amyotrophic lateral sclerosis (ALS) in order to characterize the pathophysiology and accelerate the management of the disease.
- Trial name
- SLA-PlaQ (NCT07479017)
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Tours
Amyotrophic Lateral Sclerosis, ALS
Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS
This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability and routine disease progression measures (ALSFRS-R and Vital…
- Trial name
- NCT04165850
- Testing
- Fixed dose combination Ciprofloxacin/Celecoxib
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- NeuroSense Therapeutics Ltd.
ALS
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis
The purpose of this research study is to evaluate the safety and effectiveness of Ranolazine, and how well it is tolerated in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03472950
- Testing
- Ranolazine 500 MG, Ranolazine 1000 MG
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Kansas Medical Center
Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders
Validation of a New Device to Measure Neuromuscular Disease Progression
There is a great need for the development of sensitive outcomes that allow experimental drugs to be tested in human subjects more efficiently.
- Trial name
- ATLIS (NCT00606918)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Frontotemporal Lobar Degeneration, Amyotrophic Lateral Sclerosis
Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS)
The project focuses on C9orf72, the most frequent genetic form of frontotemporal dementias (FTD, or frontotemporal lobar degeneration, FTLD) and amyotrophic lateral sclerosis (ALS).
- Trial name
- PREV-DEMALS (NCT02590276)
- Testing
- characterization
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
ALS (Amyotrophic Lateral Sclerosis)
Amyotrophic Lateral Sclerosis Registry in Thailand
This is a prospective, observational, multicenter registry designed to collect comprehensive clinical, genetic, and outcome data from patients diagnosed with amyotrophic lateral sclerosis (ALS) across Thailand.
- Trial name
- Thai ALS Regis (NCT07175935)
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Chulalongkorn University
Amyotrophic Lateral Sclerosis
A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)
This is a study to evaluate the safety and clinical effects of 4 oral doses of TCH346 compared to placebo in patients with mild or mild to moderate stages of ALS.
- Trial name
- NCT00230074
- Testing
- TCH346
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Novartis
Amyotrophic Lateral Sclerosis (ALS)
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
- Trial name
- UNITE-ALS (NCT07023835)
- Testing
- 50 mg Usnoflast, 75 mg Usnoflast
- Where
- 49 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- Zydus Therapeutics Inc.
Spinal Cord Injury, ALS (Amyotrophic Lateral Sclerosis)
Clinical Outcome Assessment for AT & BCI
Many individuals with severe motor impairments rely on Assistive Technologies (ATs) or Brain-Computer Interfaces (BCIs) to interact with digital devices such as their computers.
- Trial name
- NCT07407725
- Testing
- Eye Tracker, Mouth Operated Joystick, Non-invasive electroencephalogram (EEG) Headset
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shirley Ryan AbilityLab
Amyotrophic Lateral Sclerosis, Parkinson Disease
A Systematic Investigation of Phonetic Complexity Effects on Articulatory Motor Performance in Progressive Dysarthria
The goal is to improve the fundamental knowledge about articulatory motor performance in people with Lou Gehrig's disease (also known as ALS) and Parkinson's disease (PD), in order to develop more sensitive assessments for…
- Trial name
- NCT03613038
- Testing
- Phonetic complexity effects on speech motor performance
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Amyotrophic Lateral Sclerosis (ALS)
Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis
Weight loss is a known negative prognostic factor in amyotrophic lateral sclerosis (ALS). Over the last years, various interventional studies targeting the energy deficit in ALS yielded promising results; however,it is still…
- Trial name
- PEGASUS (NCT06877143)
- Testing
- 100% of individual calory requirement, 120% of individual calory requirement
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- University of Ulm
Amyotrophic Lateral Sclerosis
Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)
The investigators want to test feasibility of a structured program of telesurveillance and home cough assistance for ALS patients.
- Trial name
- NCT00613899
- Testing
- telesurveillance
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione Salvatore Maugeri
Amyotrophic Lateral Sclerosis
A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis
This is a Phase 2a single-centre, open single-arm study in patients with Amyotrophic Lateral Sclerosis (ALS) of intermediate progression rate. Eligible subjects will be administered weekly doses of ILB.
- Trial name
- NCT03613571
- Testing
- ILB
- Where
- Sweden
- Volunteers
- 13 people
- Sponsor
- TikoMed AB
ALS (Amyotrophic Lateral Sclerosis)
Tofersen in Non-SOD1 ALS
The goal of this clinical trial is to evaluate whether tofersen is safe and effective in adults with non-SOD1 ALS. Tofersen is currently approved by the U.S. Food and Drug Administration to treat SOD1-ALS.
- Trial name
- NCT07294144
- Testing
- Tofersen
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Amyotrophic Lateral Sclerosis
Regulatory T Cells for Amyotrophic Lateral Sclerosis
Phase 1 Safety Run-in Study of 6 patients followed by Phase 1b Randomized, Double Blind, Placebo Control Trial of CK0803, neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells in additional 60 patients…
- Trial name
- REGALS (NCT05695521)
- Testing
- CK0803, Excipient
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Cellenkos, Inc.
Amyotrophic Lateral Sclerosis
Impact of Nuedexta on Bulbar Physiology and Function in ALS
Nuedexta is FDA approved for the treatment of pseudobulbar affect in ALS patients and anecdotal reports of improvements in speech, salivation or swallowing have been reported.
- Trial name
- NCT03883581
- Testing
- dextromethorphan HBr and quinidine sulfate
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Florida